Kardigan raises $400M in IPO to back three clinical-stage cardio drugsnews2026-06-18T00:48:18+00:00June 18th, 2026|Endpoints News|
Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamnews2026-06-11T13:32:29+00:00June 11th, 2026|Endpoints News|
Parabilis CEO Mathai Mammen on biotech’s record IPOnews2026-06-10T17:24:13+00:00June 10th, 2026|Endpoints News|
Parabilis’ $670M IPO sets new biotech record, will fund cancer drugnews2026-06-10T01:21:40+00:00June 10th, 2026|Endpoints News|
Parabilis Medicines charts $413M IPO to back peptide pipelinenews2026-06-04T13:04:21+00:00June 4th, 2026|Endpoints News|
Kardigan readies Nasdaq IPO to back three cardio drugsnews2026-05-27T00:15:45+00:00May 27th, 2026|Endpoints News|
Parabilis reveals IPO plans the day after Regeneron deal as listings heat upnews2026-05-20T10:40:54+00:00May 20th, 2026|Endpoints News|
Odyssey raises more than $300M as biotech goes public in IPOnews2026-05-08T01:44:43+00:00May 8th, 2026|Endpoints News|
Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debutnews2026-05-01T11:34:58+00:00May 1st, 2026|Endpoints News|
Odyssey Therapeutics will try again to IPO, this time in a warmer marketnews2026-04-20T00:54:19+00:00April 20th, 2026|Endpoints News|
